Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Ligand Binding Sites02:40

Ligand Binding Sites

12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identification of a Potent and Selective Small-Molecule Inhibitor Targeting the nNOS-PDZ Domain that Exhibits Rapid <i>In Vivo</i> Antidepressant Efficacy.

Journal of medicinal chemistry·2026
Same author

Microstructure and Transport Properties of CaCl<sub>2</sub>-CaI<sub>2</sub> Molten Salt: A First-Principles Molecular Dynamics Study.

Materials (Basel, Switzerland)·2026
Same author

Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers.

Journal of medicinal chemistry·2026
Same author

Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer.

Journal of medicinal chemistry·2026
Same author

Deciphering How Clustered O‑Glycosylation Shapes Substrate-Binding Preferences in an Intrinsically Disordered Protein Region.

JACS Au·2026
Same author

Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.

Therapeutic advances in hematology·2026
Same journal

Ciliary flow and morphology shape mass transport at the surface and within gastrovascular cavities of black corals.

Communications biology·2026
Same journal

Virus-mediated prokaryotic community adaptation dynamics under thermal stress in municipal organic solid waste microbiomes.

Communications biology·2026
Same journal

Multi-omics insights into the woolly trait of Saussurea medusa and the plant's coordinated regulation of flavonoid biosynthesis.

Communications biology·2026
Same journal

Loss contexts enhance dorsolateral prefrontal interpersonal neural synchrony during successful human deceptive recommendations.

Communications biology·2026
Same journal

Neuro-regulator role of H<sub>2</sub>S in astrocyte activation and its effects on neurological damage and behavior of VPA-exposed rats.

Communications biology·2026
Same journal

Temporal orchestration of transcriptional and epigenomic programming underlying maternal embryonic diapause in a cricket model.

Communications biology·2026
查看所有相关文章

相关实验视频

Updated: May 22, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K

一个基于结构的框架,用于选择性抑制剂设计和优化.

Yurong Zou1, Tao Guo1, Zhiyuan Fu1

  • 1State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Communications biology
|March 13, 2025
PubMed
概括
此摘要是机器生成的。

我们开发了CMD-GEN,这是一个创新的框架,用于生成针对特定蛋白质点的药物分子. 这种方法改善了分子特性,并使选择性抑制剂设计成为可能,通过湿实验室实验验证实了这一点.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.1K

相关实验视频

Last Updated: May 22, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.1K

科学领域:

  • 计算化学是一种计算化学.
  • 药物发现 药物发现
  • 医学中的人工智能.

背景情况:

  • 基于结构的药物设计 (SBDD) 使用目标结构来创建有效的化合物.
  • 深度生成模型有助于结构特定的分子生成,但面临着制药数据的局限性,导致低于最佳的特性和不稳定的构造.
  • 现有的方法往往忽略了结合口袋相互作用,并与选择性抑制剂设计作斗争.

研究的目的:

  • 引入粗粒度和多维数据驱动分子生成 (CMD-GEN),这是一个解决当前结构特定分子生成局限性的框架.
  • 通过整合联体蛋白复合信息和粗粒度药点来增强类似药物的分子的生成.
  • 为了提高药物发现产生的分子的稳定性和选择性.

主要方法:

  • CMD-GEN采用分层架构,将3D分子生成分解为药点采样,化学结构生成和构造对齐.
  • 它利用从扩散模型中取样的粗粒度药点来丰富训练数据,并与药物样分子连接连接物-蛋白质复合体.
  • 该框架包含了多维数据驱动的方法,用于在结合口袋内生成分子.

主要成果:

  • 在基准测试中,CMD-GEN与现有方法相比表现优越,有效控制药物相似性.
  • 该框架成功生成了三种合成致命目标的分子,展示了其在复杂的药物发现场景中的适用性.
  • 用PARP1/2抑制剂进行湿实验室验证证实了CMD-GEN在设计选择性抑制剂方面的潜力.

结论:

  • CMD-GEN为结构特定的分子生成提供了强大的框架,克服了数据限制并改善了分子特性.
  • 层次化的方法减轻了不稳定性问题,并增强了具有有利构造的药物样分子的生成.
  • 在药物发现中,CMD-GEN显着有望推动选择性抑制剂设计,实验验证证明了这一点.